Marksans Pharma Ltd (MARKSANS) Stock Price & News

MARKSANS:NSE

Marksans Pharma Ltd

₹314.15

+0.59%

(+1.85) 1D

Nov 3, 3:30:00 PM GMT+5:30 · INR

All symbols

	Symbol	Price	Change	% Change

Next call in 40:43:06

Thu, Nov 5, 5:30 AM

Fiscal period

Q2 2027

- / ₹3.50

Revenue / Est. (INR)

- / 8.86B

Fiscal Q2 2027 earnings call

Waiting for the earnings call

At a glance: upcoming earnings

Insights from the latest news and reports

Previous reportsAll values in INR

Loading Previous Earnings...

All values in INR	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Revenue	7.20B	7.54B	8.56B	8.41B
Cost of goods sold	3.09B	3.16B	4.51B	3.43B
Cost of revenue	3.09B	3.16B	4.51B	3.43B
Research and development expenses	-	-	-	-
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	1.04B	1.12B	1.21B	1.14B
Operating expense	2.94B	3.02B	2.33B	3.09B
Total operating expenses	6.03B	6.18B	6.85B	6.53B
Operating income	1.18B	1.36B	1.72B	1.88B
Other non operating income	215.72M	201.44M	-441.86M	63.99M
EBT including unusual items	1.33B	1.51B	2.00B	2.07B
EBT excluding unusual items	1.33B	1.51B	1.99B	2.07B
Income tax expense	341.95M	369.34M	509.66M	471.64M
Effective tax rate	25.65%	24.52%	25.48%	22.83%
Other operating expenses	1.64B	1.65B	881.88M	1.70B
Net income	982.50M	1.13B	1.48B	1.57B
Net profit margin	13.64%	15.01%	17.30%	18.69%
Earnings per share	-	2.50	3.27	3.47
Interest and investment income	-	-	276.78M	-
Interest expense	-58.15M	-59.35M	-63.11M	-
Net interest expenses	-58.15M	-59.35M	213.67M	-
Depreciation and amortization charges	269.16M	243.27M	242.88M	248.64M
EBITDA	1.43B	1.50B	1.87B	2.04B
Gain or loss from assets sale	-	-	-	-

Finance